

ASX ANNOUNCEMENT

13 September 2022

Radiopharmaceuticals Expert Joins Clarity as Chief Scientific Officer

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the appointment of Dr Jeffrey Norenberg as Chief Scientific Officer (CSO), effective immediately.

Dr Norenberg has more than three decades of experience in radiopharmaceuticals across both the academic and biotechnology sectors. He is a globally recognised industry expert in the design and development of novel targeted radioligands for molecular imaging and therapy.

Dr Norenberg is a Professor Emeritus of Pharmacy and Anesthesiology and Critical Care Medicine and was the Director of Radiopharmaceutical Sciences at the University of New Mexico Health Sciences Center (UNM HSC) for 27 years. His work in the development of radiopharmaceuticals has resulted in 11 patents, more than 100 scholarly works and more than US\$26.5 million in funding for basic and clinical research. He has also been instrumental in 13 Phase I first-in-human studies of investigational new drugs. Prior to joining Clarity, Dr Norenberg co-founded iSeek Biopharma and was Vice-President of Chemistry at Invicro, a Contract Research Organisation (CRO) specialising in imaging in clinical trials. At Invicro, he led the external manufacturing division responsible for developing and producing novel imaging radioligands for use in clinical trials.

Clarity’s Executive Chairman, Dr Alan Taylor commented, “We are very pleased to welcome Jeff to our team at this pivotal time for Clarity. Jeff brings a wealth of highly relevant and valuable expertise in the development and commercialisation of radiopharmaceuticals to the role of CSO at Clarity. Our unique platform allows for the commercialisation of myriad of products that specifically leverage the many benefits of the perfect pairing of copper isotopes, unlike other radiopharmaceutical companies that have disparate assets in their portfolios. We look forward to working together with Jeff and leveraging these advantages to reach our ultimate goal of developing next-generation radiopharmaceuticals that will improve treatment outcomes for children and adults with cancer.”

Dr Jeffrey Norenberg commented, “I am excited to be joining Clarity at this important time in its journey. What drew me to the role was the unique opportunity with the Targeted Copper Theranostic (TCT) platform to develop next-generation radiopharmaceuticals based on Cu-64 and Cu-67. These two isotopes of copper have the ideal physical characteristics for imaging and therapy applications. Beside the impressive pace and breadth of the current clinical program, Clarity is uniquely positioned to develop and commercialise a significant number of new TCT products.

“Radiopharmaceuticals are one of the most exciting areas of global pharmaceutical development right now, yet the industry is suffering from a range of manufacturing and supply chain challenges. The TCT platform of products, enabled by the SAR Technology, is ideally positioned to deliver the clinical, logistical and environmental benefits to patients and treating staff while also substantially growing radiopharmaceuticals in oncology in an effective and sustainable way.”

Dr Norenberg has a Doctor of Pharmacy from University of Washington and a PhD in Molecular Medicine from Erasmus University in Rotterdam. He is also a Fellow of the American Society of Health-System Pharmacists, the American Pharmacists Association, the American College of Nuclear Medicine, and the Society of Nuclear Medicine and Molecular Imaging. He has served on the Board of Directors of the Society of Nuclear Medicine and Molecular Imaging, the Education Research Foundation for Nuclear Medicine, the American Board of Science in Nuclear Medicine, and as a delegate to the United States Pharmacopeia Convention. He was a Board-Certified Nuclear Pharmacist for 30 years and has been Executive Director and Chairman of the National Association of Nuclear Pharmacies for more than 20 years.

Clarity’s current CSO, Dr Matt Harris, will continue to serve the Company in a newly created role as Director of Technology, where he will provide strategic advice to the Discovery and pre-clinical team, as well as work closely with the Executive Directors on other strategic matters.

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

www.claritypharmaceuticals.com

For more information, please contact:

Clarity Pharmaceuticals

Dr Alan Taylor

Executive Chairman

ataylor@claritypharm.com

Catherine Strong

Investor/Media Relations

cstrong@citadelmagnus.com

+61 406 759 268

This announcement has been authorised for release by the Executive Chairman.